NFKB1 and neoplasm: Nevertheless, clinical use of MALT1 protease inhibitors could be limited by (a) incomplete blockade of MALT1-dependent NF-κB activity within tumor cells due to the inability of protease inhibitors to abrogate MALT1 scaffolding activity, and (b) unintended systemic autoimmunity and multiorgan inflammation that can be seen in the setting of selective MALT1 protease inhibition without concomitant inhibition of MALT1 scaffolding activity (25–29).